Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹231 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
₹37.1 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Gufic Biosciences reported Q3 FY26 revenue of ₹231.1 crore, flat sequentially, as a conscious ₹14-16 crore revenue hit from restructuring critical care and SPARSH distribution to reduce debtor days from 140 to 120 masked underlying growth. Exports grew ~40% YoY, while domestic branded business grew only ~8% due to the working capital correction. Indore plant utilization reached ~36-38 crore quarterly output (from 20-25 crore), with EU GMP audit completed in December and certificate expected by March/April, enabling regulated market exports from Q4/Q1. Management guided 15% minimum revenue growth for FY27, with EBITDA margins expected to improve from 16% to 19% as Indore utilization exceeds 50%. Key risk: debt remains elevated at ₹375 crore, with no reduction expected before FY28.
Colored figures show movement against the previous available record.
Guidance to track
- Management guided a minimum 15% topline growth for FY27, with potential upside to 20% if positive factors materialize.
- As Indore utilization exceeds 50%, EBITDA margin expected to rise from current 16% to 19%, and to 20-21% at >75% utilization.
- EU audit completed in December 2025; certificate expected by March or April, enabling regulated market exports from Q4/Q1.
- Licensing deal with a Canadian company for dermal fillers; product launch expected in June-July to complement botox portfolio.
Risks flagged
- Total debt stands at ₹375 crore and is expected to remain at that level through FY27, limiting ability to reduce interest burden.
- The restructuring of critical care and SPARSH distribution could continue to impact revenue in Q4, with an additional ₹3-5 crore hit expected.
- Export revenue from Indor hinges on timely receipt of EU GMP certificate; any delay could push back revenue contribution.
- Employee expenses have risen to ~₹40 crore per quarter and are expected to increase 7% annually, pressuring margins until Indore scales.
Key quotes
- We don't want to compromise the ramp up in terms of the backing capital by just in the Indian market still give those 3Bs without any recourse.
- I always feel that when we putting me on the block 15% is high time we give you bare minimum and whatever goes beyond we all should be happy.
- After 2-3 years when the capacity utilization of indoor will rise more than 50%, we expect the margin again margin will be raised from 16% to 19%.
Research modules